Archives

by in
Entry Author Date Location
After Unlikely Idenix Sale, Renaud Jumps to RaNA to Outfox Junk DNA 12/01/14 Boston
BioMarin Gambles $840M on Prosensa’s Duchenne Drug 11/24/14 San Francisco
East Coast Biotech Roundup: Regeneron, Sage, Tara, Alnylam, & More 11/14/14 Boston
East Coast Biotech Roundup: Sarepta, Aegerion, Syros, Aileron & More 10/31/14 Boston
More Drama for Sarepta as FDA Delays Duchenne Drug, Shares Tank 10/27/14 Boston
What Seattle Needs (Part 1): “Semi-Successful” Biotech Companies 10/06/14 Seattle
John Maraganore: From “Prototypical Geek” To Canny Alnylam Chief 09/07/14 Boston
Mapp’s Ebola Drug Shows Promise, But Making More Will Take Time 08/15/14 San Diego
East Coast Biotech Roundup: Emulate, Accelerator, Retrophin, & More 08/01/14 Boston
BioCryst Bets on New Ebola Drug to Fight Bioterror, Outbreak Threats 07/24/14 Raleigh Durham
East Coast Biotech Roundup: Regeneron, Sarepta, Jounce, & More 07/11/14 Boston
RNA Therapeutics Are Here to Stay 06/05/14 San Diego
East Coast Biotech Roundup: Bristol, PTC, Ophthotech, & More 05/27/14 Boston
East Coast Biotech Roundup: Sarepta, Alkermes, Boston Biotech, & More 04/25/14 Boston
Sarepta to Submit Application for Duchenne Drug, Shares Boom 04/21/14 Boston
Supreme Court Should Scale Back Securities Class Actions 03/04/14 National
East Coast Biotech Roundup: Sigal, Radius, SHIN-NY, & More 02/28/14 Boston
East Coast Biotech Roundup: JP Morgan Edition 01/17/14 Boston
What Biotech Pros Will Be Chirping About at JP Morgan This Week 01/13/14 National
What Was Hyped, and What Fell Out of Favor, This Year in Biotech 12/16/13 National
Building Biotechs to Last: The Photos 12/12/13 San Francisco
Building Biotechs to Last: See the Agenda for Monday 12/05/13 San Francisco
3 Life Sciences Companies That Are Built to Last 12/02/13 National
Building Biotechs to Last: A Sneak Peek at the Agenda for Dec. 9 11/19/13 San Francisco
East Coast Biotech Roundup: Sarepta, Zalicus, Alkermes, & More 11/15/13 Boston
In Defense of Sarepta’s Chris Garabedian 11/14/13 National
Sarepta Shares Crumble As FDA Calls New Drug Application “Premature” 11/12/13 Boston
Building Biotechs to Last: See Bonnie Anderson, Dan Bradbury & More 11/07/13 Boston
Lessons from the St. Louis Cardinals and ‘Building Biotechs to Last’ 10/30/13 San Francisco
Profiles in Perseverance: Building Biotechs to Last. Coming Dec. 9 10/18/13 San Francisco
Page 1 of 2 next page »